PRQR Stock Recent News
PRQR LATEST HEADLINES
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ProQR (NASDAQ: PRQR ) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (NYSE: LLY ). This agreement concerns ProQR's Axiomer RNA editing platform.
Shares of ProQR Therapeutics NV PRQR, +1.85% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, +2.33% aimed at making new genetic medicines. The companies had first said they would collaborate in 2021.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES Europe, that is being held November 16-18, 2022 in Vienna, Austria.
ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?